Department of Pharmacology, School of Medicine of Ribeirao Preto, University of Sao Paulo, 3900 Bandeirantes avenue, Ribeirao Preto-SP, Brazil.
Curr Neuropharmacol. 2017;15(2):291-299. doi: 10.2174/1570159x14666160509123955.
Panic disorder (PD) is a disabling psychiatry condition that affects approximately 5% of the worldwide population. Currently, long-term selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for PD; however, the common side-effect profiles and drug interactions may provoke patients to abandon the treatment, leading to PD symptoms relapse. Cannabidiol (CBD) is the major non-psychotomimetic constituent of the Cannabis sativa plant with antianxiety properties that has been suggested as an alternative for treating anxiety disorders. The aim of the present review was to discuss the effects and mechanisms involved in the putative anti-panic effects of CBD.
electronic database was used as source of the studies selected selected based on the studies found by crossing the following keywords: cannabidiol and panic disorder; canabidiol and anxiety, cannabidiol and 5-HT1A receptor).
In the present review, we included both experimental laboratory animal and human studies that have investigated the putative anti-panic properties of CBD. Taken together, the studies assessed clearly suggest an anxiolytic-like effect of CBD in both animal models and healthy volunteers.
CBD seems to be a promising drug for the treatment of PD. However, novel clinical trials involving patients with the PD diagnosis are clearly needed to clarify the specific mechanism of action of CBD and the safe and ideal therapeutic doses of this compound.
惊恐障碍（PD）是一种致残性精神疾病，影响着全球约 5%的人口。目前，长期使用选择性 5-羟色胺再摄取抑制剂（SSRIs）是 PD 的一线治疗方法；然而，常见的副作用和药物相互作用可能会促使患者放弃治疗，导致 PD 症状复发。大麻二酚（CBD）是大麻植物中主要的非致幻性成分，具有抗焦虑特性，被认为是治疗焦虑症的一种替代方法。本综述旨在讨论 CBD 抗惊恐作用的潜在机制和效果。
本研究使用电子数据库作为研究来源，通过交叉以下关键词来选择研究：大麻二酚和惊恐障碍；大麻二酚和焦虑；大麻二酚和 5-HT1A 受体。
在本综述中，我们纳入了同时研究动物和人类的实验性实验室研究，以评估 CBD 的抗惊恐作用。综合来看，这些研究明确表明 CBD 在动物模型和健康志愿者中具有抗焦虑样作用。
CBD 似乎是治疗 PD 的一种有前途的药物。然而，显然需要涉及 PD 诊断患者的新临床试验来阐明 CBD 的具体作用机制以及该化合物的安全和理想治疗剂量。
